Results confirmed positive impact of GLP-1 receptor agonists on MACE outcomes in patients with T2D but also revealed promising trends regarding heart failure outcomes in terms of reduced rate of heart failure-related events (30). The gene discussed is GLP1R; the disease is heart failure.